Conmed Corp (CNMD) valuation
Conmed P/E ratio history
Conmed trades at 18.3 times its earnings over the last twelve months and 9.4 times the earnings analysts expect over the next twelve. At its last 9 fiscal year ends its P/E ranged from 16.1 (year to Dec 2024) to 400.0 (year to Dec 2020), with a median of 53.7.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $40.60 | $1.51 | 26.9 | 9.0 |
| Dec 31, 2024 | $68.44 | $4.25 | 16.1 | 14.8 |
| Dec 31, 2023 | $109.51 | $2.04 | 53.7 | 26.2 |
| Dec 31, 2022 | $88.64 | -$2.68 | n/m | 26.7 |
| Dec 31, 2021 | $141.76 | $1.94 | 73.1 | 39.1 |
| Dec 31, 2020 | $112.00 | $0.28 | 400.0 | — |
| Dec 31, 2019 | $111.83 | $0.95 | 117.7 | — |
| Dec 31, 2018 | $64.20 | $1.41 | 45.5 | — |
| Dec 31, 2017 | $50.97 | $1.97 | 25.9 | — |
| Dec 31, 2016 | $44.17 | $0.52 | 84.9 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Conmed valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| ConmedCNMD | $1.33B | 18.3 | 9.4 | 1.0 |
| OmerosOMER | $1.33B | 10.7 | — | 34.8 |
| Tandem Diabetes CareTNDM | $1.31B | — | — | 1.3 |
| Us Physical TherapyUSPH | $1.31B | — | 27.6 | 1.6 |
| Nutex HealthNUTX | $1.38B | 7.7 | 7.3 | 1.6 |
| AnaptysbioANAB | $1.41B | — | 10.8 | 5.9 |
| Opko HealthOPK | $1.25B | — | — | 2.1 |
| Tyra BiosciencesTYRA | $1.25B | — | — | — |
| Innovage HoldingINNV | $1.25B | — | 20.4 | 1.3 |
| Peer median | 9.2 | 15.6 | 1.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: CNMD financials · CNMD returns
No forecast, no recommendation. This page describes Conmed Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.